Delphinidin-Rich Maqui Berry Extract (Delphinol®) Lowers Fasting and Postprandial Glycemia and Insulinemia in Prediabetic Individuals during Oral Glucose Tolerance Tests

Jorge L Alvarado, Andrés Leschot, Álvaro Olivera-Nappa, Ana-María Salgado, Hernán Rioseco, Carolina Lyon, Pilar Vigil, Jorge L Alvarado, Andrés Leschot, Álvaro Olivera-Nappa, Ana-María Salgado, Hernán Rioseco, Carolina Lyon, Pilar Vigil

Abstract

Delphinidin anthocyanins have previously been associated with the inhibition of glucose absorption. Blood glucose lowering effects have been ascribed to maqui berry (Aristotelia chilensis) extracts in humans after boiled rice consumption. In this study, we aimed to explore whether a standardized delphinidin-rich extract from maqui berry (Delphinol) affects glucose metabolism in prediabetic humans based on glycemia and insulinemia curves obtained from an oral glucose tolerance test (OGTT) after a challenge with pure glucose. Volunteers underwent four consecutive OGTTs with at least one week washout period, in which different doses of Delphinol were administered one hour before glucose intake. Delphinol significantly and dose-dependently lowered basal glycemia and insulinemia. Lower doses delayed postprandial glycemic and insulinemic peaks, while higher doses reversed this tendency. Glycemia peaks were dose-dependently lowered, while insulinemia peaks were higher for the lowest dose and lower for other doses. The total glucose available in blood was unaffected by treatments, while the total insulin availability was increased by low doses and decreased by the highest dose. Taken together, these open exploratory results suggest that Delphinol could be acting through three possible mechanisms: by inhibition of intestinal glucose transporters, by an incretin-mediated effect, or by improving insulin sensitivity.

Conflict of interest statement

Competing InterestsThis study was supported by an unconditional research grant from MNL-Chile to the Reproductive Health Research Institute, Pontificia Universidad Católica de Chile, Santiago, Chile.

Figures

Figure 1
Figure 1
Mean glycemia variation during OGTT for all volunteers treated with four different Delphinol doses of nil (control), 60, 120, and 180 mg, at four different occasions with several washout days in between experiments. Sixty minutes after Delphinol intake, participants presented with dose-dependent lowering of basal blood glucose. At this time, 75 g of glucose was consumed and resulting postprandial glucose levels are presented. Statistically significant (α = 0.05) altered values compared to untreated control are indicated by an asterisk.
Figure 2
Figure 2
Mean insulinemia variation during OGTT for all volunteers treated with four different Delphinol doses of nil (control), 60, 120, and 180 mg, at four different occasions with several washout days in between experiments. Sixty minutes after Delphinol intake, participants presented with dose-dependent lowering of basal blood glucose. At this time, 75 g of glucose was consumed and resulting postprandial glucose levels are presented. Statistically significant (α = 0.05) altered values compared to untreated control are indicated by an asterisk.
Figure 3
Figure 3
(a) Mean glycemia variation during OGTT for all volunteers treated with each separate Delphinol dose. Basal and postprandial glycemia levels are presented, in order to compare the tendencies observed at each time point depending on the dose administered. (b) Time normalized area under the glycemia curve for each dose with the contribution of each time segment. (c) Maximum glycemia peak for each dose, with regression line and 95% confidence intervals, slope value, and associated significance level. Statistically significant (α = 0.05) altered values compared to untreated control are indicated by an asterisk.
Figure 4
Figure 4
(a) Mean insulinemia variation during OGTT for all volunteers treated with each separate Delphinol dose. Basal and postprandial insulinemia levels are presented, in order to compare the tendencies observed at each time point depending on the dose administered. (b) Time normalized area under the insulinemia curve for each dose with the contribution of each time segment. (c) Maximum insulinemia peak for each dose. Statistically significant (α = 0.05) altered values compared to untreated control are indicated by an asterisk.

References

    1. Ludwig D. S. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. The Journal of the American Medical Association. 2002;287(18):2414–2423. doi: 10.1001/jama.287.18.2414.
    1. Kharroubi A. T., Darwish H. M. Diabetes mellitus: the epidemic of the century. World Journal of Diabetes. 2015;6(6):850–867. doi: 10.4239/wjd.v6.i6.850.
    1. Williamson G. Possible effects of dietary polyphenols on sugar absorption and digestion. Molecular Nutrition and Food Research. 2013;57(1):48–57. doi: 10.1002/mnfr.201200511.
    1. Bahadoran Z., Mirmiran P., Azizi F. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. Journal of Diabetes & Metabolic Disorders. 2013;12, article 43:1–7. doi: 10.1186/2251-6581-12-43.
    1. Rossetti L., Smith D., Shulman G. I., Papachristou D., DeFronzo R. A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. The Journal of Clinical Investigation. 1987;79(5):1510–1515. doi: 10.1172/jci112981.
    1. Scapagnini G., Davinelli S., Kaneko T., et al. Dose response biology of resveratrol in obesity. Journal of Cell Communication and Signaling. 2014;8(4):385–391. doi: 10.1007/s12079-014-0257-3.
    1. Wedick N. M., Pan A., Cassidy A., et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. American Journal of Clinical Nutrition. 2012;95(4):925–933. doi: 10.3945/ajcn.111.028894.
    1. Cassidy A., Mukamal K. J., Liu L., Franz M., Eliassen A. H., Rimm E. B. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013;127(2):188–196. doi: 10.1161/circulationaha.112.122408.
    1. Samieri C., Sun Q., Townsend M. K., Rimm E. B., Grodstein F. Dietary flavonoid intake at midlife and healthy aging in women. The American Journal of Clinical Nutrition. 2014;100(6):1489–1497. doi: 10.3945/ajcn.114.085605.
    1. Hanhineva K., Törrönen R., Bondia-Pons I., et al. Impact of dietary polyphenols on carbohydrate metabolism. International Journal of Molecular Sciences. 2010;11(4):1365–1402. doi: 10.3390/ijms11041365.
    1. Schäfer A., Högger P. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit α-glucosidase. Diabetes Research and Clinical Practice. 2007;77(1):41–46. doi: 10.1016/j.diabres.2006.10.011.
    1. Törrönen R., McDougall G. J., Dobson G., et al. Fortification of blackcurrant juice with crowberry: impact on polyphenol composition, urinary phenolic metabolites, and postprandial glycemic response in healthy subjects. Journal of Functional Foods. 2012;4(4):746–756. doi: 10.1016/j.jff.2012.05.001.
    1. Hidalgo J., Flores C., Hidalgo M. A., et al. Delphinol® standardized maqui berry extract reduces postprandial blood glucose increase in individuals with impaired glucose regulation by novel mechanism of sodium glucose cotransporter inhibition. Panminerva Medica. 2014;56(supplement 3):1–7.
    1. Watson R. R., Schönlau F. Nutraceutical and antioxidant effects of a delphinidin-rich maqui berry extract Delphinol®: a review. Panminerva Medica. 2015;63(2, supplement 1):1–12.
    1. Davinelli S. I., Bertoglio J. C., Zarrelli A., Pina R., Scapagnini G. A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (DelphinolⓇ) on oxidative stress biomarkers. Journal of the American College of Nutrition. 2015;34(34, supplement 1):28–33.
    1. Romanucci V., D'Alonzo D., Guaragna A., et al. Bioactive compounds of aristotelia chilensis stuntz and their pharmacological effects. Current Pharmaceutical Biotechnology. 2016;17(6):513–523. doi: 10.2174/1389201017666160114095246.
    1. Valentine V. The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management. Clinical Diabetes. 2012;30(4):151–155. doi: 10.2337/diaclin.30.4.151.
    1. Rojo L. E., Ribnicky D., Logendra S., et al. In vitro and in vivo anti-diabetic effects of anthocyanins from Maqui Berry (Aristotelia chilensis) Food Chemistry. 2012;131(2):387–396. doi: 10.1016/j.foodchem.2011.08.066.
    1. Hoggard N., Cruickshank M., Moar K. M., et al. A single supplement of a standardised bilberry (Vaccinium myrtillus L.) extract (36% wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle. Journal of Nutritional Science. 2013;2, article e22:9. doi: 10.1017/jns.2013.16.
    1. Cameron A. R., Anton S., Melville L., et al. Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a. Aging Cell. 2008;7(1):69–77. doi: 10.1111/j.1474-9726.2007.00353.x.

Source: PubMed

3
Abonner